SCHEMBL17071973

SCHEMBL17071973

CC(=O)c1c(F)cccc1-c1noc(C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.45
RAB9A P51151 9/20 0.45
NPC1 O15118 8/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HCRTR1 O43613 2/20 0.42
HCRTR2 O43614 2/20 0.42
BDKRB1 P46663 1/20 0.42
PLK1 P53350 1/20 0.40
MAOA P21397 1/20 0.40
BLVRB P30043 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6901661 0.89 NPC1 (0.51) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL17069772 0.85 PDK2 (0.45) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL20169439 0.85 BDKRB1 (0.47) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL6901655 0.85 HCRTR1 (0.53) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL18594627 0.81 PDK2 (0.42) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL2642361 0.79 PDK2 (0.49) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL2642358 0.79 NPC1 (0.49) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL11921136 0.79 L3MBTL1 (0.51) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL2642324 0.79 L3MBTL1 (0.51) PDK2RAB9ANPC1SMN1; SMN2GAA
SCHEMBL17071981 0.78 L3MBTL1 (0.45) PDK2RAB9ANPC1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9586950-B2 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-20160304490-A1 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-10-20 US disclosed
US-20150252033-A1 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252033-A1 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 PDK2 1869/4885RAB9A 3166/4885NPC1 638/4885
US-20160304490-A1 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY4R PDK2 1300/4885RAB9A 2705/4885NPC1 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.